StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.69 | $0.64 | -6.67% | 0.2M |
| 05-12 | $0.63 | $0.68 | +7.14% | 0.2M |
| 05-13 | $0.69 | $0.66 | -4.67% | 0.1M |
| 05-14 | $0.66 | $0.66 | +0.59% | 0.1M |
| 05-15 | $0.65 | $0.65 | -0.48% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-07-29 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $61.20K | $39.00K | $241.00K | $166.00K | $124.00K |
Operating Income | Not available | $-5.96M | $-22.27M | $-15.88M | $-10.18M |
Net Income | Not available | $-4.35M | $-23.76M | $-17.17M | $-5.69M |
EPS (Diluted) | $-0.08 | $-0.08 | $-1.23 | $-0.97 | $-0.62 |
Total Assets | Not available | $29.82M | $8.56M | $8.18M | $9.90M |
Total Liabilities | Not available | $19.27M | $20.32M | $15.71M | $39.76M |
Cash & Equivalents | Not available | $25.25M | $3.74M | $3.56M | $5.29M |
Free Cash Flow OCF − CapEx | Not available | Not available | $-18.38M | $-12.52M | $-8.19M |
Shares Outstanding | Not available | 68.93M | 23.26M | 21.52M | 21.52M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.